Cover Image
市場調查報告書

全球病毒感染治療藥市場預測

Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics

出版商 GBI Research 商品編碼 357639
出版日期 內容資訊 英文 179 Pages
訂單完成後即時交付
價格
Back to Top
全球病毒感染治療藥市場預測 Global Viral Infections Market to 2021 - Promising New Competitors and Expanding Treatment Population to Offset Increased Uptake of Generics
出版日期: 2016年04月05日 內容資訊: 英文 179 Pages
簡介

全球病毒感染治療藥市場,從2014年的740億美元,到2021年擴大到1,176億美元,預計2014年∼2021年以6.8%的年複合成長率成長。

本報告提供病毒感染治療藥市場相關調查分析,上市產品,開發平台,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 上市產品

  • 複數的適應症
  • 人免疫力缺乏病毒 (HIV)
  • C型肝炎病毒
  • B型肝炎病毒
  • 流感病毒

第4章 開發平台

  • 概要
  • 開發中產品:各開發階段、分子類型
  • 開發中產品:各分子標的
  • 臨床實驗情形
  • 主要的開發中產品的評估

第5章 複數方案的市場預測

  • 收益分析:各分子標的
  • 收益、市場佔有率分析:各企業

第6章 企業分析與地位

  • 企業形勢

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC406MR

Executive Summary

Viruses are infectious particles comprising a nucleic acid core – consisting of either DNA or RNA – and a protein coat known as a capsid. Infections attributable to viral pathogens are transmitted, directly or indirectly, from one person to another or from animal to human. Viruses replicate by exploiting the resources of their host cells, usually to the detriment of the host. As viral pathogens are exceptionally diverse, the morbidity associated with viral infections varies significantly depending on the virus in question. This report covers all viral infections, although particular focus is given to four key indications within this disease cluster: Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and influenza. The global viral infections market was valued at $74.0 billion in 2014, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 6.8%, reaching $117.6 billion in 2021. Key drivers of this growth will be the expanding treatment population and uptake of recently approved highly priced antiviral agents, as well as promising late-stage candidates that are expected to be priced highly.

Scope

  • The viral infections market is large and growing rapidly.
  • How do epidemiology trends differ among the key indications?
  • What therapeutic options exist for preventing and treating viral infections?
  • Which products and companies dominate the market?
  • The pipeline is innovative and diverse.
  • What is the proportion of early- to late-stage pipeline products?
  • Which molecular targets are most prominent within the pipeline? .
  • How do the key indications differ in terms of molecule type?
  • Considerable market growth is anticipated throughout 2021.
  • Which products will contribute to this growth most significantly?
  • Will the current market leaders retain their dominance over the forecast period?
  • Deal values for licensing and co-development deals range considerably.
  • How many strategic consolidations have been completed in the past decade?
  • Which types of assets attract the largest deal values?

Reasons to buy

This report will allow you to -

  • Examine the current clinical and commercial landscape by considering disease pathogenesis, treatment options and key marketed products.
  • Appreciate how the four key indications - HIV, HCV, HBV and influenza - differ in terms of epidemiology, symptoms and co-morbidities and complications.
  • Identify trends and developments, in terms of molecule type and molecular target, within the overall viral infections pipeline, as well as for each of the four key indications.
  • Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
  • Recognize how the evolving treatment landscape will drive market growth to 2021 and understand the contributions that different products, molecular targets and companies will make to this growth.
  • Understand how strategic consolidations have shaped the current pipeline and marketed product landscapes.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Human Immunodeficiency Virus (HIV)
    • 2.2.1. Overview
    • 2.2.2. Symptoms
    • 2.2.3. Co-morbidities and Complications
    • 2.2.4. Epidemiology
  • 2.3. Hepatitis C Virus
    • 2.3.1. Overview
    • 2.3.2. Symptoms
    • 2.3.3. Co-morbidities and Complications
    • 2.3.4. Epidemiology
  • 2.4. Hepatitis B Virus
    • 2.4.1. Overview
    • 2.4.2. Symptoms
    • 2.4.3. Co-morbidities and Complications
    • 2.4.4. Epidemiology
  • 2.5. Influenza
    • 2.5.1. Overview
    • 2.5.2. Symptoms
    • 2.5.3. Co-morbidities and Complications
    • 2.5.4. Epidemiology
  • 2.6. Etiology and Pathogenesis of Viral Infections
  • 2.7. Treatment for Viral Infections
    • 2.7.1. Vaccines
    • 2.7.2. Antiviral Agents

3. Marketed Products

  • 3.1. Multiple Indications
    • 3.1.1. Viread-Gilead
    • 3.1.2. Epivir/Epivir-HBV-ViiV Healthcare
    • 3.1.3. Pegasys-F. Hoffmann La Roche
  • 3.2. Human Immunodeficiency Virus (HIV)
    • 3.2.1. Truvada-Gilead
    • 3.2.2. Atripla-Gilead
    • 3.2.3. Stribild-Gilead
    • 3.2.4. Tivicay-ViiV Healthcare
    • 3.2.5. Triumeq-ViiV Healthcare
    • 3.2.6. Genvoya-Gilead
  • 3.3. Hepatitis C Virus (HCV)
    • 3.3.1. Olysio-Janssen
    • 3.3.2. Sovaldi and Harvoni-Gilead
    • 3.3.3. Zepatier-Merck and Co.
  • 3.4. Hepatitis B Virus
    • 3.4.1. Baraclude-Bristol-Myers Squibb
  • 3.5. Influenza Virus
    • 3.5.1. Tamiflu-Roche

4. Pipeline

  • 4.1. Overview
  • 4.2. Pipeline Products by Stage of Development and Molecule Type
  • 4.3. Pipeline Products by Molecular Target
  • 4.4. Clinical Trials Landscape
    • 4.4.1. Clinical Trial Failure Rates
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Cumulative Clinical Trial Size
    • 4.4.5. Conclusion
  • 4.5. Assessment of Key Pipeline Products
    • 4.5.1. Sofosbuvir in Combination with Velpatasvir-Gilead
    • 4.5.2. Tenofovir alafenamide fumarate-Gilead
    • 4.5.3. Descovy-Gilead
    • 4.5.4. Cobicistat, darunavir, emtricitabine and TAF-Johnson & Johnson
    • 4.5.5. Beclabuvir hydrochloride-Bristol-Myers Squibb
    • 4.5.6. V-212-Merck

5. Multi-scenario Market Forecast to 2021

  • 5.1. Revenues Analysis by Molecular Target
    • 5.1.1. Reverse Transcriptase
    • 5.1.2. Nonstructural Protein 5B Polymerase and Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A
    • 5.1.3. HIV Integrase
    • 5.1.4. Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase
    • 5.1.5. NS3-4A Protease/Nonstructural Protein 5A
  • 5.2. Revenue and Market Share Analysis by Company
    • 5.2.1. Gilead Sciences-Monopolization of Market to Continue Throughout 2021
    • 5.2.2. Merck-Uptake of Zepatier and Gardasil 9 to Encourage Strong Growth
    • 5.2.3. GlaxoSmithKline-Tivicay and Triumeq to Propel Company Revenues
    • 5.2.4. Johnson and Johnson-Market Share to Dwindle as Sales for Prezista and Olysio Decline
    • 5.2.5. Bristol-Myers Squibb-Marginalization Due to Patent Expirations

6. Company Analysis and Positioning

  • 6.1. Company Landscape

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Value, Year and Indication
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Molecular Target and Value
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Value, Year and Indication
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Molecular Target and Value

8. Appendix

  • 8.1. References
  • 8.2. Abbreviations
  • 8.3. Table of All Pipeline Products
  • 8.4. Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Market Size and Revenue Forecasts
    • 8.4.4. Pipeline Analysis
    • 8.4.5. Competitive Landscape
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Common Routes of Viral Entry
  • Table 2: Viral Infections Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016
  • Table 3: Viral Infections Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016
  • Table 4: Table of All Pipeline Products

List of Figures

  • Figure 1: Viral Infections Therapeutics Market, Major Markets, HIV Prevalence ('000), 2014-2021
  • Figure 2: Viral Infections Therapeutics Market, Major Markets, HCV Prevalence ('000), 2014-2021
  • Figure 3: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Viread ($m), 2006-2021
  • Figure 4: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Epivir/Epivir-HBV ($m), 2006-2021
  • Figure 5: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Pegasys ($m), 2006-2021
  • Figure 6: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Truvada ($bn), 2006-2021
  • Figure 7: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Atripla ($bn), 2006-2021
  • Figure 8: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Stribild ($bn), 2012-2021
  • Figure 9: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tivicay ($bn), 2013-2021
  • Figure 10: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Triumeq ($bn), 2015-2021
  • Figure 11: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Genvoya ($bn), 2016-2021
  • Figure 12: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Olysio ($m), 2013-2021
  • Figure 13: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Sovaldi and Harvoni ($bn), 2013-2021
  • Figure 14: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Zepatier ($bn), 2016-2021
  • Figure 15: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Baraclude ($m), 2006-2021
  • Figure 16: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tamiflu ($m), 2006-2021
  • Figure 17: Overall Pharmaceutical Industry Pipeline by Therapy Area, Global, 2016
  • Figure 18: Viral Infections Therapeutics Market, Global, Pipeline for Viral Infections by Stage of Development and Molecule Type, 2016
  • Figure 19: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2016
  • Figure 20: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2016
  • Figure 21: Viral Infections Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
  • Figure 22: Viral Infections Therapeutics Market, Global, Breakdown of Viral Surface Protein, Immune Mediator and Polymerase Molecular Targets, 2016
  • Figure 23: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2016
  • Figure 24: Viral Infections Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006-2016
  • Figure 25: Viral Infections Therapeutics Market, Global, Clinical Trial Failure and Attrition Rates by Indication and Stage of Development (%), 2006-2016
  • Figure 26: Viral infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 27: Viral Infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 28: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Indication and Stage of Development (Months), 2006-2016
  • Figure 29: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (Months), 2006-2016
  • Figure 30: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (Months), 2006-2016
  • Figure 31: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Indication and Stage of Development (Participants), 2006-2016
  • Figure 32: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016
  • Figure 33: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016
  • Figure 34: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Indication and Stage of Development (participants), 2006-2016
  • Figure 35: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016
  • Figure 36: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016
  • Figure 37: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Sofosbuvir in Combination with Velpatasvir ($bn), 2016-2021
  • Figure 38: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for TAF ($bn), 2016-2021
  • Figure 39: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Descovy ($bn), 2016-2021
  • Figure 40: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Cobicistat in combination with darunavir, emtricitabine and TAF ($bn), 2016-2021
  • Figure 41: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Beclabuvir Hydrochloride ($bn), 2016-2021
  • Figure 42: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for V-212 ($m), 2017-2021
  • Figure 43: Viral Infections Therapeutics Market, Global, Market Size ($bn), 2014-2021
  • Figure 44: Viral Infections Therapeutics Market, Global, Forecast Revenues for Strongest Commercial Products, 2014-2021
  • Figure 45: Viral Infections Therapeutics Market, Global, Premium and Generic Market Share ($bn), 2014-2021
  • Figure 46: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Reverse Transcriptase ($bn), 2014-2021
  • Figure 47: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A, ($bn), 2014-2021
  • Figure 48: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting HIV Integrase, ($bn), 2014-2021
  • Figure 49: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase, ($bn), 2014-2021
  • Figure 50: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting NS3-4A Protease/Nonstructural Protein 5A, ($bn), 2014-2021
  • Figure 51: Viral Infections Therapeutics Market, Global, Revenues by Company, 2014-2021
  • Figure 52: Viral Infections Therapeutics Market, Global, Companies by Compound Annual Growth Rate (CAGR), 2014-2021
  • Figure 53: Viral Infections Therapeutics Market, Global, Companies by Market Share, 2014-2021
  • Figure 54: Viral Infections Therapeutics Market, Revenues by Route of Acquisition, 2014-2021
  • Figure 55: Viral Infections Therapeutics Market, Gilead Sciences Annual Revenues ($bn), 2014-2021
  • Figure 56: Viral Infections Therapeutics Market, Global, Gilead Sciences Annual Revenues by Product ($m), 2014-2021
  • Figure 57: Viral Infections Therapeutics Market, Merck Annual Revenues ($bn), 2014-2021
  • Figure 58: Viral Infections Therapeutics Market, Global, Merck Annual Revenues by Product ($m), 2014-2021
  • Figure 59: Viral Infections Therapeutics Market, GlaxoSmithKline Annual Revenues ($bn), 2014-2021
  • Figure 60: Viral Infections Therapeutics Market, Global, GlaxoSmithKline Annual Revenues by Product ($m), 2014-2021
  • Figure 61: Viral Infections Therapeutics Market, Johnson and Johnson Annual Revenues ($bn), 2014-2021
  • Figure 62: Viral Infections Therapeutics Market, Global, Johnson and Johnson Annual Revenues by Product ($m), 2014-2021
  • Figure 63: Viral Infections Therapeutics Market, Bristol-Myers Squibb Annual Revenues ($bn), 2014-2021
  • Figure 64: Viral Infections Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenues by Product ($m), 2014-2021
  • Figure 65: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016
  • Figure 66: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016
  • Figure 67: Viral Infections Therapeutic Market, Global, Proportion of Total Company Revenue Attributed to Viral Infection Products, 2014-2021
  • Figure 68: Viral Infections Therapeutics Market, Global, Licensing Deals by Region, Deal Value and Year, 2006-2016
  • Figure 69: Viral Infections Therapeutics Market, Global, Licensing Deals by Indication and Deal Value, 2006-2016
  • Figure 70: Viral Infections Therapeutics Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016
  • Figure 71: Viral Infections Therapeutics Market, Global, Licensing Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016
  • Figure 72: Viral Infections Therapeutics Market, Global, Co-development Deals by Region, Deal Value and Year, 2006-2016
  • Figure 73: Viral Infections Therapeutics Market, Global, Co-development Deals by Indication and Deal Value, 2006-2016
  • Figure 74: Viral Infections Therapeutics Market, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016
  • Figure 75: Viral Infections Therapeutics Market, Global, Co-development Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016
Back to Top